Product Description
Autologous muscle derived stem cells for Gastro-Intestinal Repair (AMDC-GIR) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02838316)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cook
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Enuresis|Urinary Incontinence, Stress
Phase 2: Deglutition Disorders|Fecal Incontinence
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02838316 |
NCT02838316 | P1 |
Active, not recruiting |
Deglutition Disorders |
2026-12-01 |
50% |
2025-02-20 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
2021-005399-21 |
STEFFI-FU | P2 |
Completed |
Fecal Incontinence |
2024-05-24 |
2025-07-09 |
Treatments |
|
NCT03104517 |
CELLEBRATE | P3 |
Active, not recruiting |
Enuresis|Urinary Incontinence, Stress |
2025-02-01 |
58% |
2025-02-12 |
Primary Endpoints |
NCT05421689 |
REVIVE | P2 |
Active, not recruiting |
Deglutition Disorders |
2026-12-31 |
12% |
2024-12-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |